Core Viewpoint - The company, Gilead Sciences-B (01672), has seen a significant stock price increase of over 7%, currently trading at 11.62 HKD with a transaction volume of 56.46 million HKD, following the announcement of a share buyback plan using up to 300 million HKD [1] Group 1: Share Buyback Announcement - The board of directors has decided to exercise the buyback authorization and will repurchase shares in the open market based on market conditions [1] - The company plans to utilize a maximum of 300 million HKD for the proposed share buyback [1] Group 2: Clinical Data and Future Plans - Dongwu Securities has indicated that the company has multiple catalysts in the second half of the year, with several important clinical data releases expected [1] - The company is anticipated to report top-line data for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I by Q4 2025, and for ASC30 subcutaneous Phase II by Q1 2026 [1] - The company expects to submit 2-3 new IND applications to the FDA within the next 6-9 months, including a dual-target peptide weight loss pipeline [1]

Core Viewpoint - The company, Gilead Sciences-B (01672), has seen its stock price increase by over 7%, currently trading at 11.62 HKD with a transaction volume of 56.46 million HKD, following the announcement of a share buyback plan worth up to 300 million HKD [1] Group 1: Share Buyback Announcement - The board of directors has decided to exercise the buyback authorization and will repurchase shares in the open market based on market conditions [1] - The company plans to utilize a maximum of 300 million HKD for the proposed share buyback [1] Group 2: Clinical Data and Future Plans - Dongwu Securities has indicated that the company has several catalysts in the second half of the year, with multiple important clinical data expected to be disclosed [1] - The company is projected to read out top-line data for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I by Q4 2025, and for ASC30 subcutaneous Phase II by Q1 2026 [1] - The company anticipates submitting 2-3 new IND applications to the FDA within the next 6-9 months, including a dual-target peptide weight loss pipeline [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 5%, currently trading at 10.88 HKD with a transaction volume of 92.59 million HKD, following the announcement of positive results from its ASC30 oral GLP-1R agonist study [1] Group 1: Clinical Trial Results - Gilead announced that at the 61st European Association for the Study of Diabetes (EASD) conference in Vienna, it reported results from its ASC30 oral GLP-1R agonist 28-day multiple dose escalation study [1] - The ASC30 oral tablet showed an average weight loss of up to 6.5% after 28 days of treatment, adjusted for placebo [1] - The efficacy of ASC30 is attributed to its higher oral drug exposure, with good safety and tolerability, experiencing only mild to moderate gastrointestinal adverse events [1] Group 2: Future Catalysts - Dongwu Securities noted that Gilead has several catalysts in the second half of the year, with multiple important clinical data expected to be disclosed [1] - The firm anticipates that by Q4 2025, Gilead will read out phase II topline data for ASC30 oral, phase I data for ASC47, and phase I data for ASC50, with phase II topline data for ASC30 subcutaneous expected in Q1 2026 [1] - The company plans to submit 2-3 new IND applications to the FDA for its pipeline, including a dual-target peptide weight loss program, within the next 6-9 months [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 4% following the announcement of promising clinical data for its long-acting GLP-1R agonist ASC30, indicating potential for quarterly dosing in weight management [1] Group 1: Clinical Developments - Gilead announced that its small molecule GLP-1R agonist ASC30 has shown a 75-day apparent half-life in obese subjects, suggesting a long-term weight management solution [1] - The ASC30 formulation is developed using Gilead's Ultra Long-Acting Drug Development Platform (ULAP) [1] Group 2: Shareholder Commitments - Gilead's controlling shareholder has made a voluntary lock-up commitment, agreeing not to sell any shares before the release of three key clinical data points [1] - The three data points include: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025 [1] 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025 [1] 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 5% in early trading, driven by the announcement of a voluntary lock-up commitment from the controlling shareholder, which will prevent the sale of shares until key clinical data is released [1] Group 1: Clinical Trials and Data - Gilead Sciences announced that the controlling shareholder will not sell any company shares before the release of three key clinical data points: 1. Top-line data from the U.S. Phase I clinical trial of ASC47 combined with semaglutide in obese subjects, expected by the end of September 2025 2. Top-line data from the U.S. 13-week Phase IIa clinical trial of ASC30 oral tablets in obese or overweight subjects, expected by December 2025 3. Top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1][1][1] Group 2: Drug Development and Potential - The company recently announced that the small molecule GLP-1R agonist ASC30 demonstrated an apparent half-life of 75 days in obese subjects, indicating the potential for developing a long-term weight management solution with quarterly dosing [1][1] - ASC30 is developed using Gilead's Ultra-Long-Acting Drug Development Platform (ULAP), and the company has multiple pipelines relying on this platform to develop long-acting formulations, which may meet various clinical needs [1][1]

Core Viewpoint - The announcement from the company reflects a strong commitment to its long-term value and future prospects, as demonstrated by the voluntary shareholding commitment from key executives [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and He Jingdao have voluntarily committed not to sell or pledge any shares they control until the release of three key clinical trial data points [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and his wife amounts to 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1]

Core Viewpoint - The company expresses strong confidence in its long-term value and future prospects through a voluntary commitment by its founder and major shareholders to not sell any shares before the release of three key clinical trial data points [1] Group 1: Clinical Trial Data Commitments - The founder, Dr. Wu, and his spouse, Ms. He, have committed not to sell or pledge any shares they control until the following clinical data readouts: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with Semaglutide in obese subjects, expected by the end of September 2025 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by the end of December 2025 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by the end of December 2025 [1][1][1] Group 2: Shareholding Information - As of the announcement date, Dr. Wu and Ms. He hold a total of 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1][1][1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has announced a voluntary commitment by its founder and major shareholders to not sell any shares before the release of three key clinical trial data points, reflecting their confidence in the company's long-term value and future prospects [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and Ms. He Jingdao have committed to not selling or pledging any shares they control until the release of three specific clinical trial results [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide in obese subjects, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by the end of December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by the end of December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and Ms. He is approximately 576 million shares, representing about 58.03% of the company's existing issued share capital (excluding treasury shares) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出。 本公司董事（「董事」）會（「董事會」）謹此宣布，其獲告知，為表達對本公司長遠 價值及未來前景的堅定信心，吳勁梓博士（歌禮創始人、董事會主席兼首席執行 官、及本公司控股股東，「吳博士」），與何淨島（本公司執行董事及控股股東、吳 博士之配偶，「吳夫人」）一起，已自願承諾在如下3個臨床數據讀出前，不會出 售（包括但不限於出售或質押）任何由彼等或彼等各自控制的實體直接或間接實益 擁有的本公司股份（「股份」）：(i) ASC47聯合司美格魯肽在肥胖受試者中進行的 美國I期臨床研究頂線數據，預計於2025年9月底獲得；(ii) ASC30口服片在肥胖 或超重受試者中進行的美國13周IIa期臨床研究頂線數據，預計於2025年12月獲 得；及(iii) ASC50在健康受試者中進行的美國I期單劑量遞增研究頂線數據，預 計於202 ...

Core Viewpoint - Dongwu Securities reports that Gilead Sciences-B (01672) is progressing well with its pipeline for 2025, aligning with expectations, and the likelihood of successful product launches is high [1] Group 1: ASC30 Injection Data - The ASC30 injection has shown a promising apparent half-life of 75 days in obese subjects, indicating the potential for a quarterly dosing regimen for long-term weight management [1] - In the Phase Ib clinical study, no serious adverse events (SAEs) were reported, and only mild gastrointestinal-related adverse events (AEs) were observed, indicating excellent safety and tolerability for long-term use [2] Group 2: ULAP Platform and Future Developments - ASC30 is developed using Gilead's Ultra-Long-Acting Platform (ULAP), which allows for the creation of various long-acting formulations to meet diverse clinical needs [3] - The company is currently conducting a Phase IIa clinical trial for ASC30 in the U.S., utilizing the ULAP technology to achieve precise drug release and improve clinical efficacy [3] Group 3: Upcoming Catalysts and Clinical Data - The company expects to disclose significant clinical data in the second half of the year, including top-line results for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I in Q4 2025, and ASC30 subcutaneous Phase II in Q1 2026 [4] - Additionally, the company plans to submit 2-3 new IND applications to the FDA within the next 6-9 months, including a dual-target peptide weight loss pipeline [4]